Liso-cel: ASH 2022 vs SOC SCT and ASCT in RR LBCL
By Jeremy Abramson, MD
CD19 is the target of Liso-cel, which is a 4-1BB costimulated CAR T-cell. It was compared to chemotherapy based on platinum, which was then followed by BEAM. A high dose of chemotherapy is combined with an autologous stem cell transplant in the BEAM protocol. The overwhelming majority of patients had diffuse large B-cell lymphoma and had initial illness that was resistant to frontline chemotherapy and immunotherapy. In the Liso-cel arm, the duration of cytopenias was significantly longer.
On day 62, however, the majority of these patients had made a full recovery, and there was no increase in the incidence of grade 3 or higher infections. The level of neurotoxicity was also fairly low, coming in at 11%; four patients presented with grade 3 CRS (cytokine release syndrome). There were no competitions of grade 4 or 5. As a result, we believe that Liso-cel is a viable choice that is both effective and safe, and it is currently the second therapy option that is favored for patients who have early relapsed or primary refractory large B-cell lymphoma.
The majority of patients with relapsed large B-cell lymphoma after frontline chemoimmunotherapy. Liso-cel and Axi-cel are better than the standard of care we have used for decades. As of today, any patient who has primary refractory disease or disease progressing within 1 year should be referred for consideration of CAR T-cells.
Watch and Share the Video Here: https://oncologytube.com/v/41740
Read and Share the Article Here: https://oncologytube.com/v/41742
Listen and Share the Audio Podcast Here: https://oncologytube.com/v/41743
